Oxidative stress and cardiovascular disease in hemodialysis

Clinical Nephrology

Volumn 55, Issue 2, 2001, Pages 93-100

  Boaz, M ^a   Green, M ^a   Fainauru, M ^a   Smetana, S ^a  

^a WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Cardiovascular disease hemodialysis; Oxidative stress; Vitamin E

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIOXIDANT; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HEMODIALYSIS; HUMAN; INFLAMMATION; LIPID PEROXIDATION; OXIDATIVE STRESS; REVIEW;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; HYPERHOMOCYSTEINEMIA; NITRIC OXIDE; OXIDATIVE STRESS; RENAL DIALYSIS; VITAMIN E;

EID: 0035137435     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Beyond lipids - The role of the endothelium in coronary artery disease
2. Minimally modified low-density lipoprotein stimulates monocyte-endothelial interactions
3. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis
4. Lipid oxidation kinetics in hemodialysis patients with and without history of myocardial infarction
5. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients
6. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
7. Monocytes and neutrophils oxidize low-density lipoprotein making it cytotoxic
8. Cholesterol-dependent regulation of nitric oxide production: Potential role in atherosclerosis
9. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous translaminal coronary angioplasty (PTCA)
10. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells
11. Role of vitamin E in preventing the oxidation of low-density lipoprotein
12. Oxidative stress and antioxidant defenses in renal patients receiving regular hemodialysis
13. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): Amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins
14. New insights into nitric oxide and coronary circulation
15. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipemic rabbits
16. Cardiac function and hematocrit level
17. Enhanced macrophage degradation of low-density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low-density lipoproteins
18. Enhanced macrophage degradation of biologically modified low-density lipoprotein
19. Oxidative protein damage with carbohydrates and lipids in uremia: "Carbonyl Stress"
20. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease
21. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure
22. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease
23. Antioxidant vitamin intake and coronary mortality in a longitudinal population study
24. Susceptibility of erythrocyte lipids to oxidation and erythrocyte antioxidant status in myocardial infarction
25. Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients
26. Coenzyme Q1O levels, plasma lipids and peroxidation extent in renal failure and hemodialytic patients
27. Oxidative stress in hemodialysis
28. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis?
29. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease
30. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure
31. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: Is there oxidative stress in uremia?
32. Alterations in non-enzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications
33. Low-density lipoprotein cytotoxicity induced by free radical peroxidation of lipid
34. Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients
35. Impairment of endothelial functions by acute hyperhocysteinemia and reversal by antioxidant vitamins
36. Monocyte transmigration induced by modification of low-density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein
37. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: Effects of fish oil and vitamin E administration
38. Cardiac and cerebrovascular disease in chronic uremia
39. Serum and erythrocyte tocopherol in uremic patients: Effect of hemodialysis versus peritoneal dialysis
40. Lipid peroxidation abnormalities in hemodialyzed patients
41. Lipoperoxidation in plasma and red blood cells of patients undergoing hemodialysis. Vitamins A, E, and iron status
42. Endothelial cell-derived chemotactic activity for mouse peritoneal macrophages and the effects of modified forms of low-density lipoprotein
43. Oxidatively modified low-density lipoprotein: A potential role in recruitment and retention of monocytes/macrophages during atherogenesis
44. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man
45. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure
46. Inflammatory markers in men with angiographically documented coronary heart disease
47. Vitamin E consumption and the risk of coronary heart disease in men
48. Morbidity and mortality due to hyperin patients with renal failure
49. Detection of oxidants in uremid plasma by electron spin resonance spectroscopy
50. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions
51. Auto-antibody against oxidized LDL and progression of carotid atherosclerosis
52. Plasma lipids are not oxidized during hemodialysis
53. Indices of activity of the nitric oxide system in hemodialysis patients
54. Changes of antioxidative homeostasis in patients on chronic hemodialysis
55. Vitamin E consumption and the risk of coronary disease in women
56. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)
57. Serum vitamin E levels in patients with chronic renal failure
58. Malondialdehyde content of cell membranes is the most important marker of oxidative stress in haemodialysis patients
59. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure
60. Inflammation markers and coronary heart disease
61. Erythrocyte defense mechanisms against oxygen radicals in hemodialyzed uraemic children
62. Association between elevated plasma total homocysteine and increased common carotid artery wall thickness
63. Enhanced in vivo lipid peroxidation at elevated plasma total homocysteine levels
64. Advanced oxidation protein products as a novel marker of oxidative stress in uremia
65. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure
66. Role of oxidized low-density lipoprotein in atherogenesis
67. The effect of vitamin E therapy on plasma and erythrocyte lipid peroxidation in chronic hemodialysis patients
68. Evidence for the presence of oxidatively modified low-density lipoprotein, in atherosclerotic lesions of rabbit and man
69. Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in hemodialysis patients
70. Lipid peroxidation on dialysis membranes
71. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients